To assess the safety and activity of banked CD30 CAR EBVSTs, we are treating patients with multiply relapsed or refractory CD30-positive lymphomas in a phase 1 dose escalation study….We have treated 9 patients so far, all with Hodgkin lymphoma. Of these, 2 had an initial response to treatment....5 patients have had a complete response and 4 have had a partial response (overall response rate of 82%), with higher dose levels being associated with better responses...CD30.CAR EBVSTs can safely be given to allogeneic recipients and may cause significant tumor responses including complete remissions.